Latest Reported Offering
$19,999
Target Amount
$4,999,999
Maximum Amount
2025-09-29
Deadline
Security Details
Type: Common Stock
Price per share: $1.35
Price set by: N/A
Shares offered: 14,814+
Offering Costs
Cash commission: —
7 - 13 percent
Equity compensation: —
Three percent (3%) of securities of the total amount of investments raised in the offering, along the same terms as investors.
Filing history
Form C family — 7 filings| Filed | Form | File number | Portal | What it states | What the filer said |
|---|---|---|---|---|---|
| 2025-10-06 | C-U | 020-35469 | StartEngine Primary LLC | $20K target, up to $5M · Common Stock at $1.35 · closes 2025-09-29 | At the close of the offering, the issuer closed on $1,583,596.78 anhd 1,812,846 number of securities. |
| 2025-08-27 | C/A | 020-35469 | StartEngine Primary LLC | $20K target, up to $5M · Common Stock at $1.35 · closes 2025-09-29 | Issuer is updating their offering end date to September 29, 2025. |
| 2025-08-14 | C/A | 020-35469 | StartEngine Primary LLC | $20K target, up to $5M · Common Stock at $1.35 · closes 2025-08-28 | Issuer is updating their campaign page |
| 2025-06-17 | C/A | 020-35469 | StartEngine Primary LLC | $20K target, up to $5M · Common Stock at $1.35 · closes 2025-08-28 | Issuer is extending their end date to August 28th, 2025, disclosing the acquisition of Alpha Anomeric SA, and disclosing the appointment of Lance Hirsch. |
| 2025-04-29 | C-AR | 020-35469 | StartEngine Primary LLC | Revenue $0 · net income -$625K · 1 employees | — |
| 2025-03-18 | C/A | 020-35469 | StartEngine Primary LLC | $20K target, up to $5M · Common Stock at $1.35 · closes 2025-06-17 | Audited financials for FY 12/31/24 & 12/31/23 completed; prior year adjusted. Cash on hand updated to Feb 2025. Added disclosures on product status, FDA process, IP, insider investments ($6,199.20), funding goals, use of proceeds & extended end date. |
| 2025-01-29 | C | 020-35469 | StartEngine Primary LLC | $124K target, up to $1.2M · Common Stock at $1.35 · closes 2025-04-30 | — |
The reported figures behind AlphaRose Therapeutics Inc
Form C prints a most-recent and a prior fiscal year side by side but never names them. The dashboard chains every filing into those years and plots them. EDGAR still has each Form C-AR; the dashboard lays every year they filed next to it.
- Reported financials chained into fiscal years — revenue, income, assets, cash — not one filing at a time
- A sparkline on each figure so the shape is visible before the numbers
- A revenue series dated to the filings that reported it
- The campaign as filed: target, ceiling, deadline, and the portal that ran it
- Follow it, and see it change on your watchlist
Company Information
Legal Status
Corporation
Jurisdiction
DE
Date of Incorporation
2023-10-31
Website
Latest Metrics
Employees1
Total Assets$614,498
Cash on Hand$525,845
Revenues$0.00
Net Income-$625,253
Crowdfunding Portals
The intermediary named in this company’s Form C filings. Investments in a Regulation Crowdfunding offering can only be made through them.